Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Adaptimmune Therapeutics PLC stock logo
ADAP
Adaptimmune Therapeutics
$0.25
+3.5%
$0.27
$0.20
$1.48
$66.26M2.181.66 million shs459,962 shs
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
$8.95
-0.8%
$10.06
$6.02
$11.31
$1.87B1.043.03 million shs1.41 million shs
Cabaletta Bio, Inc. stock logo
CABA
Cabaletta Bio
$1.61
+0.4%
$1.71
$0.99
$8.77
$82.71M2.71.66 million shs930,473 shs
Harpoon Therapeutics, Inc. stock logo
HARP
Harpoon Therapeutics
$23.01
$22.89
$3.11
$23.21
$389.61M2.111.52 million shsN/A
PDL BioPharma, Inc. stock logo
PDLI
PDL BioPharma
$2.47
$2.47
$2.09
$3.86
N/AN/AN/AN/A
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Adaptimmune Therapeutics PLC stock logo
ADAP
Adaptimmune Therapeutics
0.00%+2.45%-11.99%-2.75%-75.39%
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
0.00%-4.43%-18.98%+30.97%+39.55%
Cabaletta Bio, Inc. stock logo
CABA
Cabaletta Bio
0.00%+2.29%-27.33%+44.68%-78.73%
Harpoon Therapeutics, Inc. stock logo
HARP
Harpoon Therapeutics
0.00%0.00%0.00%0.00%0.00%
PDL BioPharma, Inc. stock logo
PDLI
PDL BioPharma
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Adaptimmune Therapeutics PLC stock logo
ADAP
Adaptimmune Therapeutics
2.1405 of 5 stars
3.15.00.00.01.30.80.0
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
4.4751 of 5 stars
4.52.00.04.21.91.70.6
Cabaletta Bio, Inc. stock logo
CABA
Cabaletta Bio
1.5533 of 5 stars
3.52.00.00.00.00.80.6
Harpoon Therapeutics, Inc. stock logo
HARP
Harpoon Therapeutics
0.696 of 5 stars
0.00.00.04.70.02.50.0
PDL BioPharma, Inc. stock logo
PDLI
PDL BioPharma
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Adaptimmune Therapeutics PLC stock logo
ADAP
Adaptimmune Therapeutics
2.29
Hold$1.35438.51% Upside
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
2.90
Moderate Buy$16.7086.70% Upside
Cabaletta Bio, Inc. stock logo
CABA
Cabaletta Bio
3.00
Buy$14.43798.42% Upside
Harpoon Therapeutics, Inc. stock logo
HARP
Harpoon Therapeutics
0.00
N/AN/AN/A
PDL BioPharma, Inc. stock logo
PDLI
PDL BioPharma
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest HARP, BCRX, ADAP, CABA, and PDLI Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/1/2025
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$13.00 ➝ $15.00
6/30/2025
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$13.00
6/30/2025
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$16.00 ➝ $18.00
6/26/2025
Adaptimmune Therapeutics PLC stock logo
ADAP
Adaptimmune Therapeutics
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Neutral$1.50 ➝ $0.50
6/25/2025
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$17.00
6/11/2025
Cabaletta Bio, Inc. stock logo
CABA
Cabaletta Bio
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$25.00
5/16/2025
Cabaletta Bio, Inc. stock logo
CABA
Cabaletta Bio
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$17.00 ➝ $13.00
5/15/2025
Cabaletta Bio, Inc. stock logo
CABA
Cabaletta Bio
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$23.00 ➝ $25.00
5/14/2025
Adaptimmune Therapeutics PLC stock logo
ADAP
Adaptimmune Therapeutics
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$1.50 ➝ $1.00
5/14/2025
Adaptimmune Therapeutics PLC stock logo
ADAP
Adaptimmune Therapeutics
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetUnderweight ➝ Underweight$1.00 ➝ $0.46
5/7/2025
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$8.00 ➝ $11.00
(Data available from 7/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Adaptimmune Therapeutics PLC stock logo
ADAP
Adaptimmune Therapeutics
$178.03M0.37N/AN/A$0.05 per share5.02
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
$503.49M3.72N/AN/A($2.30) per share-3.89
Cabaletta Bio, Inc. stock logo
CABA
Cabaletta Bio
N/AN/AN/AN/A$3.12 per shareN/A
Harpoon Therapeutics, Inc. stock logo
HARP
Harpoon Therapeutics
$37.34M10.43N/AN/A$1.63 per share14.12
PDL BioPharma, Inc. stock logo
PDLI
PDL BioPharma
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Adaptimmune Therapeutics PLC stock logo
ADAP
Adaptimmune Therapeutics
-$70.81M-$0.27N/AN/AN/A-38.91%-163.73%-23.65%8/11/2025 (Estimated)
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
-$88.88M-$0.26N/AN/A2.55-10.62%N/A-11.06%8/4/2025 (Estimated)
Cabaletta Bio, Inc. stock logo
CABA
Cabaletta Bio
-$115.86M-$2.54N/AN/AN/AN/A-78.29%-65.68%8/6/2025 (Estimated)
Harpoon Therapeutics, Inc. stock logo
HARP
Harpoon Therapeutics
-$67.73M-$8.76N/AN/AN/A-81.68%-893.55%-45.98%N/A
PDL BioPharma, Inc. stock logo
PDLI
PDL BioPharma
N/A$0.1913.00N/AN/AN/AN/AN/A

Latest HARP, BCRX, ADAP, CABA, and PDLI Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/21/2025Q1 2025
Cabaletta Bio, Inc. stock logo
CABA
Cabaletta Bio
-$0.67-$0.71-$0.04-$0.71N/AN/A
5/13/2025Q1 2025
Adaptimmune Therapeutics PLC stock logo
ADAP
Adaptimmune Therapeutics
-$0.18-$0.18N/A-$0.18$6.55 million$7.29 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Adaptimmune Therapeutics PLC stock logo
ADAP
Adaptimmune Therapeutics
N/AN/AN/AN/AN/A
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
N/AN/AN/AN/AN/A
Cabaletta Bio, Inc. stock logo
CABA
Cabaletta Bio
N/AN/AN/AN/AN/A
Harpoon Therapeutics, Inc. stock logo
HARP
Harpoon Therapeutics
N/AN/AN/AN/AN/A
PDL BioPharma, Inc. stock logo
PDLI
PDL BioPharma
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Adaptimmune Therapeutics PLC stock logo
ADAP
Adaptimmune Therapeutics
4.24
2.02
1.79
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
N/A
2.93
2.88
Cabaletta Bio, Inc. stock logo
CABA
Cabaletta Bio
N/A
3.96
3.96
Harpoon Therapeutics, Inc. stock logo
HARP
Harpoon Therapeutics
N/A
1.89
1.89
PDL BioPharma, Inc. stock logo
PDLI
PDL BioPharma
N/AN/AN/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Adaptimmune Therapeutics PLC stock logo
ADAP
Adaptimmune Therapeutics
490265.05 million231.28 millionOptionable
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
530209.25 million199.21 millionOptionable
Cabaletta Bio, Inc. stock logo
CABA
Cabaletta Bio
5050.74 million45.03 millionOptionable
Harpoon Therapeutics, Inc. stock logo
HARP
Harpoon Therapeutics
5316.93 million14.05 millionOptionable
PDL BioPharma, Inc. stock logo
PDLI
PDL BioPharma
109N/AN/AOptionable

Recent News About These Companies

GT Biopharma Inc GTBP
Health Winners & Losers: Maxygen
PDLI Historical Data
PDL stabbed by fellow inmate
ABVC - ABVC BioPharma, Inc.
RDHL - RedHill Biopharma Ltd.
Cheap Flights from Nuremberg to Ponta Delgada
Cheap Flights from London to Ponta Delgada
LABP
Casdin Leads a Biopharma Surge
PDL BioPharma Stock To Go Ex-dividend Monday (PDLI)
PDL BioPharma Stock To Go Ex-dividend Tomorrow (PDLI)
Cramer's 'Mad Money' Recap: Politics Is Overrated
Steris (STE)

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Adaptimmune Therapeutics stock logo

Adaptimmune Therapeutics NASDAQ:ADAP

$0.25 +0.01 (+3.55%)
Closing price 07/3/2025 03:42 PM Eastern
Extended Trading
$0.25 0.00 (0.00%)
As of 07/3/2025 04:44 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; research, collaboration, and license agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.

BioCryst Pharmaceuticals stock logo

BioCryst Pharmaceuticals NASDAQ:BCRX

$8.94 -0.08 (-0.83%)
Closing price 07/3/2025 03:51 PM Eastern
Extended Trading
$8.94 0.00 (0.00%)
As of 07/3/2025 04:38 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

Cabaletta Bio stock logo

Cabaletta Bio NASDAQ:CABA

$1.61 +0.01 (+0.38%)
Closing price 07/3/2025 03:47 PM Eastern
Extended Trading
$1.64 +0.04 (+2.43%)
As of 07/3/2025 04:41 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis. It also develops DSG3-CAART, which is in Phase I/II clinical trial for the treatment of mucosal pemphigus vulgaris; and MuSK-CAART, an investigational cell therapy that is in Phase I/II clinical trial for treating patients with anti- muscle-specific kinase antibody positive myasthenia gravis. It has a collaboration with the University of Pennsylvania and the Children's Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

Harpoon Therapeutics stock logo

Harpoon Therapeutics NASDAQ:HARP

Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company develops tri-specific T cell activating construct (TriTAC) product candidate, including HPN328, which is in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors; and HPN217 that is in Phase I clinical trials for the treatment of multiple myeloma. Its preclinical stage product is HPN601 for the treatment of multiple solid tumor indications. It has a discovery collaboration and license agreement with AbbVie Biotechnology Ltd. to develop and commercialize products that incorporate its proprietary TriTAC platform technology together with soluble T cell receptors. The company was incorporated in 2015 and is headquartered in South San Francisco, California. As of March 11, 2024, Harpoon Therapeutics, Inc. operates as a subsidiary of Merck Sharp & Dohme LLC.

PDL BioPharma stock logo

PDL BioPharma NASDAQ:PDLI

PDL BioPharma, Inc. manages various patents in the United States and internationally. The company's patents cover humanization of antibodies. It also offers notes and other long-term receivables services, as well as engages in the equity investment activities. The company was formerly known as Protein Design Labs, Inc. and changed its name to PDL BioPharma, Inc. in 2006. PDL BioPharma, Inc. was founded in 1986 and is headquartered in Incline Village, Nevada.